Q4 2025 13F Holders as of 31 Dec 2025
-
Type / Class
-
Equity / Common Stock, $0.0001 par value per share
-
Shares outstanding
-
78,024,641
-
Total 13F shares
-
46,682,919
-
Share change
-
+5,032,183
-
Total reported value
-
$359,443,900
-
Put/Call ratio
-
122%
-
Price per share
-
$7.70
-
Number of holders
-
125
-
Value change
-
+$38,829,151
-
Number of buys
-
72
-
Number of sells
-
35
Institutional Holders of Corvus Pharmaceuticals, Inc. - Common Stock, $0.0001 par value per share (CRVS) as of Q4 2025
As of 31 Dec 2025,
Corvus Pharmaceuticals, Inc. - Common Stock, $0.0001 par value per share (CRVS) was held by
125 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
46,682,919 shares.
The largest 10 holders included
ORBIMED ADVISORS LLC, BlackRock, Inc., VANGUARD GROUP INC, MORGAN STANLEY, ADAMS STREET PARTNERS LLC, Point72 Asset Management, L.P., STATE STREET CORP, MPM BIOIMPACT LLC, Vivo Capital, LLC, and GEODE CAPITAL MANAGEMENT, LLC.
This page lists
125
institutional shareholders reporting positions in this security
for the Q4 2025 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.